Menu closed

You are now leaving the LillyMedical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.

Neuroscience Journal Publications

This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

For all other requests, please visit our Contact Lilly services.

Cymbalta^® (duloxetine)

Full Prescribing Information

No Publication Journals

Population pharmacokinetics of duloxetine in Japanese pediatric patients with major depressive disorder

Published Date: February 15, 2023

Efficacy and safety of duloxetine in children and adolescents with major depressive disorder in Japan: a randomized double-blind placebo-controlled clinical trial followed by an open-label long-term extension trial

Published Date: March 25, 2022

Duloxetine Exposure During Pregnancy and the Risk of Offspring Being Born Small for Gestational Age or Prematurely: A Nationwide Danish and Swedish Safety Study

Published Date: November 10, 2022

Published Date: March 25, 2022

Recovery in patients with Major Depression Disorder (MDD): Results from a 6-month, multinational, observational study

Published Date: October 4, 2021

Emgality^® (galcanezumab-gnlm)

Full Prescribing Information

Safety, Tolerability and Pharmacokinetics of Galcanezumab, an anti-CGRP antibody, in healthy Chinese participants

Published Date: September 12, 2025

Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study.

Published Date: April 6, 2024

Galcanezumab efficacy through the dosing interval in Japanese patients with episodic migraine: post hoc analysis of a phase 2 randomized trial

Published Date: September 12, 2023

Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial

Published Date: October 31, 2022

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine

Published Date: November 17, 2021

Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab

Published Date: February 3, 2025

Baseline Demographics and Disease Characteristics of Patients With Episodic or Chronic Cluster Headache: Results From Two Phase 3 Clinical Trials in Europe and North America

Published Date: December 15, 2023

Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention.

Published Date: December 6, 2023

Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.

Published Date: August 7, 2023

Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.

Published Date: May 3, 2023

Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine.

Published Date: April 27, 2023

Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study

Published Date: February 16, 2023

Reductions in Acute Medication Use and Healthcare Resource Utilization in Patients with Chronic Migraine: Findings from a Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Galcanezumab with Open-Label Extension (REGAIN)

Published Date: August 16, 2022

Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis

Published Date: August 5, 2022

Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.

Published Date: July 28, 2022

Long-Term Open-Label Safety Study of Galcanezumab in Patients with Episodic or Chronic Cluster Headache

Published Date: June 13, 2022

Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials.

Published Date: May 8, 2022

Galcanezumab for episodic and chronic cluster headache

Published Date: April 27, 2022

Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)

Published Date: April 25, 2022

Does 'wearing off' of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.

Published Date: February 17, 2022

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment

Published Date: January 18, 2022

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

Published Date: September 20, 2021

Benefit-risk assessment of galcanezumab versus placebo for the treatment of episodic and chronic migraine using the metrics of number needed to treat and number needed to harm

Published Date: July 15, 2021

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache.

Published Date: July 8, 2021

Efficacy of Galcanezumab in Patients With Episodic Cluster Headaches and a History of Preventive Treatment Failure

Published Date: June 4, 2021

Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.

Published Date: June 1, 2021

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Published Date: February 4, 2026

The Role of Income and Health Insurance on Migraine Care: Results of the OVERCOME (US) Study

Published Date: January 12, 2026

Clinical characteristics, patient burden and treatment patterns of cluster headache in Brazil: a real-world study

Published Date: December 3, 2025

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study

Published Date: September 29, 2025

Opioid Use among People with Migraine: Results of the OVERCOME (US) Study

Published Date: September 19, 2025

Patient Preferences for Self-Injectable Preventive Treatment for Migraine: A Multi-Country Discrete Choice Experiment

Published Date: August 2, 2025

Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Use in People With Migraine: Results of the OVERCOME (US) Study

Published Date: June 12, 2025

Monthly headaches and severity in patients on galcanezumab or traditional preventive migraine medication: a 24-month claims and electronic health records study

Published Date: April 11, 2025

A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland

Published Date: April 6, 2025

Patient preferences for episodic migraine medications: A discrete choice experiment of self-injectable versus oral treatments targeting calcitonin gene-related peptide pathway

Published Date: March 29, 2025

Healthcare Resource Utilization and Direct Costs Incurred Over 12 Months by Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A US Real-World Study

Published Date: March 28, 2025

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study.

Published Date: March 14, 2025

Stigmatizing attitudes toward people with migraine by people without active migraine: Results of the OVERCOME (US) study

Published Date: March 12, 2025

Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims Study

Published Date: March 1, 2025

Development of the Migraine-Related Stigma (MiRS) Questionnaire: Results of the OVERCOME (US) Study

Published Date: January 22, 2025

Treatment Patterns, Characteristics, and Probable Acute Medication Overprescription Among Patients With Migraine in Japan: A Retrospective Cross-Sectional and Longitudinal Analysis of Health Insurance Claims Data

Published Date: December 18, 2024

Interictal Burden in Migraine Patients at the Outset of CGRP Monoclonal Antibody Prevention

Published Date: December 18, 2024

Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis

Published Date: December 16, 2024

Patient-reported outcomes related to migraine burden among patients treated with standard-of-care preventive medications or calcitonin gene-related monoclonal antibodies: a United States and Europe cross-sectional survey

Published Date: November 15, 2024

Factors and Reasons Associated with Hesitating to Seek Care for Migraine: Results of the OVERCOME (US) Study

Published Date: November 2, 2024

Monitoring pregnancies exposed to galcanezumab for migraine in a United States administrative claims database

Published Date: October 7, 2024

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)

Published Date: September 19, 2024

Healthcare Resource Utilization and Direct Costs Incurred over 24 Months after Initiating Galcanezumab or Standard-of-care Preventive Migraine Treatments in the United States

Published Date: August 1, 2024

A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States

Published Date: June 19, 2024

Machine Learning Identifies Factors Most Associated with Seeking Medical Care for Migraine: Results of the OVERCOME (US) Study

Published Date: May 24, 2024

Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study

Published Date: March 28, 2024

Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.

Published Date: February 22, 2024

Published Date: February 13, 2024

Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)

Published Date: February 8, 2024

Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years

Published Date: January 24, 2024

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study.

Published Date: January 9, 2024

Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States

Published Date: December 18, 2023

Clinical characteristics and treatment patterns of patients with episodic cluster headache: results from the United States, United Kingdom and Germany.

Published Date: August 24, 2023

Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.

Published Date: January 9, 2023

A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.

Published Date: September 16, 2022

Healthcare Resource Utilization and Costs Associated with Treatment Among Patients Initiating Calcitonin Gene-Related Peptide Inhibitors versus Other Preventive Migraine Treatments in the US.

Published Date: August 1, 2022

Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.

Published Date: July 12, 2022

Prevalence Rates of Primary Headache Disorders and Evaluation and Treatment Patterns Among Korean Neurologists.

Published Date: May 20, 2022

Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study.

Published Date: March 28, 2022

Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.

Published Date: January 25, 2022

Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.

Published Date: November 30, 2021

Kisunla^™ (donanemab-azbt)

Full Prescribing Information

Safety, tolerability, and pharmacokinetics of donanemab in healthy Chinese participants: A phase 1, randomized, double-blind, placebo-controlled study

Published Date: May 20, 2025

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

Published Date: June 28, 2023

Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease

Published Date: February 18, 2023

The iADRS as an integrated measure of cognition and function: Psychometric evidence from recent clinical trials in early symptomatic AD

Published Date: September 14, 2025

Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease

Published Date: September 2, 2025

The Alzheimer’s Disease Cooperative Study – Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity

Published Date: July 1, 2025

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease

Published Date: August 17, 2023

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

Published Date: June 28, 2023

APOE e4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.

Published Date: May 19, 2023

'Time Saved' As A Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

Published Date: May 3, 2023

Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease

Published Date: March 9, 2023

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.

Published Date: February 16, 2023

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Published Date: December 1, 2022

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.

Published Date: October 17, 2022

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.

Published Date: September 12, 2022

Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.

Published Date: June 4, 2022

Published Date: April 2, 2026

Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Published Date: December 1, 2025

Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

Published Date: October 15, 2025

Donanemab exposure-response in early symptomatic Alzheimer's disease

Published Date: July 16, 2025

The Effect of Modified Donanemab Titration on Amyloid-Related Imaging Abnormalities with Edema/Effusions and Amyloid Reduction: 18-Month Results from TRAILBLAZER-ALZ 6

Published Date: July 5, 2025

Revision of the ADCS-ADL dependence score algorithm to assess level of supportive care needed across the Alzheimer's Disease continuum

Published Date: July 1, 2025

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

Published Date: May 20, 2025

Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction

Published Date: April 2, 2025

Published Date: March 13, 2025

Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial

Published Date: April 6, 2024

How donanemab data address the coverage with evidence development questions.

Published Date: February 7, 2024

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease

Published Date: August 17, 2023

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Published Date: August 10, 2023

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Published Date: July 17, 2023

No Publication Journals

Reyvow^® (lasmiditan)

Full Prescribing Information

Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-glycoprotein and Breast Cancer Resistance Protein Substrates

Published Date: August 11, 2023

Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study.

Published Date: May 25, 2023

Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine

Published Date: September 22, 2022

Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial.

Published Date: September 22, 2022

Safety profile of lasmiditan in patients with migraine in an Asian population

Published Date: July 19, 2022

Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial.

Published Date: June 24, 2022

Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.

Published Date: March 25, 2024

Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial

Published Date: March 23, 2023

Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post-hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial

Published Date: September 17, 2022

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine

Published Date: August 18, 2022

The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials

Published Date: July 2, 2022

Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial

Published Date: June 20, 2022

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis.

Published Date: April 26, 2022

Safety Findings from CENTURION, a Phase 3 Consistency Study of Lasmiditan for the Acute Treatment of Migraine

Published Date: November 6, 2021

Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study

Published Date: October 13, 2021

A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN

Published Date: August 28, 2021

Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.

Published Date: August 6, 2021

Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain

Published Date: June 1, 2021

Patient-doctor communication in migraine: Results from the OVERCOME (Japan) 2nd Study

Published Date: October 28, 2025

The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study

Published Date: June 19, 2025

Real-world use of over-the-counter medications by patients with migraine in Japan: Results from the OVERCOME (Japan) 2nd Study

Published Date: May 7, 2025

The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study

Published Date: December 21, 2024

Underrecognition of migraine-related stigmatizing attitudes and social burden: Results of the OVERCOME Japan study

Published Date: July 25, 2024

Acute treatment patterns, migraine burden, and healthcare resource use in people with migraine: results from the OVERCOME (EU) observational study

Published Date: April 16, 2024

Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study.

Published Date: January 4, 2024

Serotonin Syndrome in the Acute Treatment Landscape of Migraine: the Lasmiditan Experience

Published Date: October 26, 2023

Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™

Published Date: February 3, 2023

Can't find what you're looking for? Contact us for answers to your medical questions.

Copyright
Terms of Use
Privacy Statement
Consumer Health Privacy Notice
Accessibility Statement
Sitemap

This site is intended for US Healthcare Professionals only.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

Your Privacy Choices

Cookie Settings

Neuroscience Journal Publications

Cymbalta: Phase I (No Publications Available) Phase I (No Publications Available)

Cymbalta: Phase II (No Publications Available) Phase II (No Publications Available)

Cymbalta: Phase III Phase III

Cymbalta: Phase IV & Real World Evidence Phase IV & Real World Evidence

Emgality: Phase I Phase I

Emgality: Phase II Phase II

Emgality: Phase III Phase III

Emgality: Phase IV & Real World Evidence Phase IV & Real World Evidence

Kisunla: Phase I Phase I

Kisunla: Phase II Phase II

Kisunla: Phase III Phase III

Kisunla: Phase IV & Real World Evidence (No Publications Available) Phase IV & Real World Evidence (No Publications Available)

Reyvow: Phase I Phase I

Reyvow: Phase II Phase II

Reyvow: Phase III Phase III

Reyvow: Phase IV & Real World Evidence Phase IV & Real World Evidence